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Linking a dermal permeation and an inhalation model to a
simple pharmacokinetic model to study airborne exposure to
di(n-butyl) phthalate
Matthew Lorber1, Charles J. Weschler2,3, Glenn Morrison4, Gabriel Bekö3, Mengyan Gong5, Holger M. Koch6, Tunga Salthammer7,
Tobias Schripp7, Jørn Toftum3 and Geo Clausen3
Six males clad only in shorts were exposed to high levels of airborne di(n-butyl) phthalate (DnBP) and diethyl phthalate (DEP) in
chamber experiments conducted in 2014. In two 6 h sessions, the subjects were exposed only dermally while breathing clean air
from a hood, and both dermally and via inhalation when exposed without a hood. Full urine samples were taken before, during,
and for 48 h after leaving the chamber and measured for key DnBP and DEP metabolites. The data clearly demonstrated high levels
of DnBP and DEP metabolite excretions while in the chamber and during the ﬁrst 24 h once leaving the chamber under both
conditions. The data for DnBP were used in a modeling exercise linking dose models for inhalation and transdermal permeation
with a simple pharmacokinetic model that predicted timing and mass of metabolite excretions. These models were developed and
calibrated independent of these experiments. Tests included modeling of the “hood-on” (transdermal penetration only), “hood-off”
(both inhalation and transdermal) scenarios, and a derived “inhalation-only” scenario. Results showed that the linked model tended
to duplicate the pattern of excretion with regard to timing of peaks, decline of concentrations over time, and the ratio of DnBP
metabolites. However, the transdermal model tended to overpredict penetration of DnBP such that predictions of metabolite
excretions were between 1.1 and 4.5 times higher than the cumulative excretion of DnBP metabolites over the 54 h of the
simulation. A similar overprediction was not seen for the “inhalation-only” simulations. Possible explanations and model
reﬁnements for these overpredictions are discussed. In a demonstration of the linked model designed to characterize general
population exposures to typical airborne indoor concentrations of DnBP in the United States, it was estimated that up to
one-quarter of total exposures could be due to inhalation and dermal uptake.
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INTRODUCTION
Diethyl phthalate (DEP) and di(n-butyl) phthalate (DnBP) are
among the most abundant man-made compounds found in
indoor air.1–3 Furthermore, the metabolites of phthalate esters,
including these two, are often the most abundant metabolites of
man-made compounds found in human urine.4 Humans are
exposed to these compounds in their diets via inhalation, dust
ingestion, and dermal absorption.5–7 Clark et al.8 have shown that
pathways other than diet can be important for these two
phthalates, and in particular, consumer products may dominate
in certain circumstances for DEP. Dust ingestion may be important
for DnBP, but it is anticipated to be much less important for DEP.
DnBP is typically present in household dust at a mass fraction of
5 to 100 μg/g, whereas DEP, with a higher vapor pressure, has a
typical mass fraction of 1 to 10 μg/g (see Table 3 in Langer et al.9).
Given the elevated concentrations of DEP and DnBP in indoor air,
inhalation could be an important route of exposure. A recent
study with human volunteers under controlled conditions has
demonstrated that, following a 6 h exposure, dermal uptake from
air is comparable to inhalation intake.10
Dermal uptake of small organic molecules, directly from air, has
been amply documented.11–13 However, only in the past several
years has uptake from air been considered a potentially signiﬁcant
pathway for certain higher molecular weight organic compounds
such as phthalate esters.14 Weschler and Nazaroff15 developed a
steady-state model to estimate the “overall dermal permeability
coefﬁcient” (i.e., from air through skin to blood) for organic
compounds based on their fundamental physical–chemical
properties. Their model was based on a mechanistic model
developed by Mitragotri16 to predict transdermal permeability of
organic species from aqueous solution. Gong et al.17 extended
these ideas and crafted a transient model to estimate the
transport of a gas-phase organic compound from air through
skin to blood under dynamic conditions. Morrison et al.18 modiﬁed
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the transient model of Gong et al.17 to include skin surface lipids
as a layer distinct from the underlying stratum corneum.
Very few physiologically based pharmacokinetic (PBPK) models
have been developed for phthalates, and the ones that have
been published were used to study disposition of phthalates in
laboratory animals.19–21 The authors are not aware of the use of
PBPK models to study human exposure to plasticizers. However,
simple empirical pharmacokinetic (PK) models have been devel-
oped for humans and applied to general population exposure
situations.22–25 These models for di-2-ethylhexylphthalate (DEHP),
DnBP, diisobutyl phthalate (DiBP), and Hexamoll DINCH were
developed from human dosing experiments on one or more
individuals who self-dosed at levels known to be substantially
higher than background (but still known to be well below levels
of health concern), and then metabolites were measured in blood
for up to 6 h and urine samples for up to 48 h after dosing.
The models were built around the data—they were toxicokinetic
models whose purpose was to replicate the experimental data.
As such, they had “blood” and “bladder” reservoirs that
maintained the mass balance of phthalate metabolites and were
able to predict the pattern of excretion of the metabolites seen in
the experiments. Once calibrated, they can be used in general
exposure scenarios where the exposure inputs are time and
amount of phthalate assumed to be absorbed as parent into the
blood reservoir in units of mass/time (or mass/body weight–time),
and time and amount of urine voids. Of course, the assumption in
these types of general model usages is that the calibrated
parameters developed in the controlled human dosing experi-
ments are suitable for general use.
In the present paper, a linked modeling approach was used to
study the exposure of individuals to airborne vapor-phase DnBP.
Chamber experiments with human subjects exposed to elevated
levels of vapor-phase DnBP10 provided the data for this linked
modeling study. These data included concentrations of DnBP in
the chamber, and times and full urine volumes that were
measured for DnBP metabolites starting from the volunteers’
time in the chamber (6 h) and for 48 subsequent hours. The
transient dermal model developed by Gong et al.17 was the initial
candidate model selected to estimate transport of gas-phase DnBP
from air through the skin to blood. Initial testing of the model of
Gong et al.17 with these data sets led to the realization that the
modeled absorption of DnBP was substantially more than could
be accounted for by the measured excretion of the DnBP meta-
bolites. This led to changes in the model, as described in Morrison
et al.18 and summarized below. This adjusted model was linked to
the toxicokinetic model developed by Lorber and Koch25 to model
excretion patterns of DnBP metabolites. In addition to modeling
dermal uptake from air to blood, inhalation intake was also
modeled, taking advantage of the fact that a portion of the data
from these experiments was generated with the volunteers
breathing the air that contained elevated levels of DnBP. Dynamic
modeling of dermal uptake and inhalation intake provided a time-
varying dose to blood that was input for the PK model; the PK
model then predicted the delivery and excretion of DnBP
metabolites for each of the urination events. A comparison of
predicted and observed excretions of DnBP metabolites permitted
an evaluation of the performance of the linked model approach. If
the linked model is deemed successful, it can be used to enhance
our understanding of potential exposures that are associated with
DnBP, not only in situations with unusually high air concentrations
but also under more typical indoor conditions. Such an exercise
was undertaken to conclude the analysis. A typical indoor
concentration of DnBP was determined from published measured
values. The linked models routed inhalation and dermal permea-
tion exposures to the “bladder” to predict daily mass excretions of
a key DnBP metabolite. By dividing this mass by a typical daily
urine volume, we were able to compare the resulting concentra-
tion with measured concentrations in a national survey. This
permits a rough estimation of the relative contribution of
inhalation and dermal uptake to total phthalate uptake from all
pathways.
METHODS
Chamber Experiments
In 2014, chamber experiments were conducted to evaluate transdermal
uptake of DnBP and DEP directly from air.10 These experiments took place
at the Technical University of Denmark, and the protocol was approved by
the Capital Region of Denmark Committee for Research Ethics. Participants
provided informed consent before participation. The portion of the
experiments entailing exposure to DnBP were used in the present
modeling study. Six male volunteers, aged 27 to 66 years, were divided
into groups 1 and 2. Each 3-member group was exposed to elevated
concentrations of DnBP in a 55 m3 chamber for 6 h. Group 1 comprised
participants who are identiﬁed as P1, P2, and P3 in this paper, and group 2
includes P4, P5, and P6. On Tuesday of the ﬁrst week, group 1 was exposed
while wearing hoods and breathing air with background (low) concentra-
tions of DnBP; hence, exposure was primarily via the dermal pathway. On
Tuesday of the second week, group 1 was exposed without hoods and
breathing chamber air; hence, exposure was via both the dermal and the
inhalation pathway. The conditions were reversed for group 2, who were
exposed without hoods on Wednesday of the ﬁrst week and while wearing
hoods on Wednesday of the second week. The concentrations of DnBP
were measured seven times in the chamber air during each exposure
period, resulting in the following average concentrations over 6 h in the
chamber: group 1: hoods on 123 μg/m3 and hoods off 140 μg/m3; group 2:
hoods on 140 μg/m3 and hoods off 114 μg/m3. During the chamber
exposures the participants were clothed only in shorts and were seated
most of the time. One or two background urine samples were taken before
entering the chamber, and the participants provided one full volume urine
sample during the chamber exposure. After leaving the chamber, full
volumes of urine were collected for each urination over the next 48 h. The
urine was subsequently analyzed for DnBP metabolites, mono-n-butyl
phthalate (MnBP), and 3-hydroxy-mono-n-butyl phthalate (3OH-MnBP).
The amounts of MnBP and 3OH-MnPB excreted at each urination provided
the key dependent observations in the present study. The independent
model inputs of inhalation intake and dermal uptake were based on the
measured air concentrations and participant speciﬁc or literature derived
parameters. Further details on the experimental design and results can be
found in Weschler et al.10
Inhalation Intake and Dermal Uptake
Inhalation intakes for modeling were calculated as the product of
individual-speciﬁc inhalation rates and the air concentration within the
chamber. The inhalation rates speciﬁc to each of the 6 participants were
developed in Weschler et al.10 (see Figure 3). They were developed for
both DEP and DnBP results; the rates for each individual were similar
between the two phthalates, although the inhalation rates between
individuals were different. The average per individual (average of
breathing rates between the two phthalates) used in this assessment
were: P1 = 0.64 m3/h, P2 = 0.72 m3/h, P3 = 0.84 m3/h, P4 = 0.63 m3/h,
P5 = 0.45 m3/h, and P6 = 0.60 m3/h. These are consistent with recommen-
dations provided by the EPA Exposure Factors Handbook (EFH):26 for “sleep
and nap” as well as “sedentary/passive” the rate is 0.26 m3/h, for “light
intensity” the rate is 0.72 m3/h, and for “moderate intensity” the rate is
1.62 m3/h. During exposures in which the participants did not wear a hood,
the measured chamber concentrations were used to calculate the
inhalation intakes. For example, for P1, the calculated inhalation intake
for the “hood-off” condition was 89.6 μg/h (i.e., 140 μg/m3× 0.64 m3/h).
During exposures in which the participants wore a hood, inhalation intakes
were calculated using the concentration of DnBP measured within
the breathing hood (e.g., for P1 the calculation is 5.7 μg/m3× 0.64 m3/
h= 3.6 μg/h).
The procedure for modeling transdermal uptake was developed in
Morrison et al.18 This model extended that of Gong et al.17 by including a
layer of skin surface lipids and the inﬂuence of clothing. Brieﬂy, dynamic
phthalate uptake by dermal capillaries depends on transport by convective
mass transfer through the air boundary layer adjacent to skin, accumula-
tion in skin surface lipids, and Fickian diffusion through the stratum
corneum and viable epidermis. After the 6 h bare-skin exposure period,
participants don clothing; in the simulation this is modeled as a perfect
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sink located very close, but not touching, the skin. All input parameters are
participant speciﬁc (air concentration and exposed skin area) and from
literature or estimated independently (the convective mass-transfer
coefﬁcient, the thickness of each layer, air layer partition coefﬁcients,
diffusion coefﬁcients). For the simulations here, we used the same set of
parameters shown in Tables 1 and 2 (nominal parameters) of Morrison
et al.18; many of these are listed in Supplementary Table S1. The dynamic
dermal uptake of DnBP was generated for each participant for both
hooded and non-hooded experiments. These results, unique to each
participant and experiment, were then used as input to the pharmaco-
kinetic model. Morrison et al.18 found that inclusion of clothing and skin
surface lipids resulted in a signiﬁcant improvement over previous models
in predictions of overall dermal uptake for the participants described in
Weschler et al.10 Predicted uptake of DEP was close to the mean value for
all participants; however, predicted uptake of DnBP was ∼ 2.3 times greater
than the measured values averaged over all participants. Inclusion of a
one-time removal of skin surface lipids to clothing made a small
improvement in the predictions for DEP and a larger improvement in
the predictions for DnBP (see Figure 4 of Morrison et al.18). As the
simulations applied in the current paper do not include removal of skin
surface lipids, they are anticipated to result in an overprediction of
transdermal uptake of DnBP that will range from a factor of 1.4 to 4.5,
depending on the individual simulated.
PK Modeling
The PK model for DnBP was described in Lorber and Koch.25 The model
contains a “blood” and a “bladder” reservoir. Intakes are deposited directly
into the “blood” reservoir as parent DnBP, and within the blood reservoir,
are metabolized to MnBP, 3OH-MnBP, 4OH-mono-n-butyl phthalate (4OH-
MnBP), and 3carboxymono-propyl phthalate (MCPP). These metabolites
are routed to the “bladder” reservoir, and the full amount in the reservoir at
the time of an urination event is excreted. The model was calibrated to
data from a single individual self-dosing with 5 mg of labeled DnBP. Six
measurements in blood up to 7 h after ingestion provided the data
necessary to calibrate the metabolism algorithm in blood. Full urine
volumes up to 48 h were obtained and also measured for DnBP
metabolites, and these data provided the necessary information to
calibrate the delivery of metabolites to the bladder reservoir. The
toxicokinetics of DnBP metabolism as determined in a human experiment
is as follows: ∼ 92% of a dose is excreted in urine as these metabolites
within 24 h, with MnBP explaining ∼ 84% of the 92%, with the other
metabolites noted explaining ∼ 8%.27 Further details of the model
development can be found in Lorber and Koch.25
All toxicokinetic parameter values determined in Lorber and Koch25
were used without change in this application. Independent inputs to the
model for the current study include the dermal uptake and inhalation
intake, both of which were input into the blood reservoir as the starting
point of the simulation. The dependent observations were the measured
metabolites in urine samples, one taken while still in the chamber, and
then every urination until 48 h after leaving the chamber for a total 54 h of
simulation. These urine samples were measured only for two of the DnBP
metabolites—MnBP and 3OH-MnBP—and hence model validation only
focuses on these two metabolites. The model was set up on an Excel
spreadsheet and run in 5 min increments for 54 h.
Simulation Strategy
Three sets of modeling exercises were undertaken:
Hood-on, dermal exposure. Generally, this simulation was a test of the
transdermal uptake modeling scenario only. There was a relatively small
inhalation intake due to the background concentration of DnBP in the
hood air, 5.7 μg/m3, compared with ~ 130 μg/m3 in chamber air. This small
inhalation intake was added to the dermal dose directly into the blood
reservoir during the simulation. Also input into the model were urination
times and volumes of urine for the six volunteers. The model predicted
mass and concentration of excreted metabolite to compare with the
corresponding measured quantities. The contribution from inhalation
intake was small compared with dermal uptake; inhalation intake was
∼ 5% of total intake.
Hood-off, dermal and inhalation exposure. Inhalation intake and dermal
uptake of DnBP were added and input into the blood reservoir at 5 min
increments. Within the blood reservoir, DnBP was metabolized, routed to
the bladder, and excreted as per the input times and volumes of urine for
each of the six volunteers.
Inhalation-only exposure. These “hood-off” experiments provide an
opportunity to evaluate the inhalation component of the linked model,
in the same way that the “hood-on” experiments provided a test of the
dermal penetration model. As there was minimal inhalation uptake during
these hood-on experiments, it can be simplistically assumed that all of the
excretion of DnBP metabolites of the participants in these hood-on
experiments was due to dermal penetration only. An “inhalation-only”
scenario was crafted from the “hood-off” experiments. First, the inhalation
exposure intake was simply calculated as in the hood-off simulations: an air
concentration times an individual-speciﬁc inhalation rate. The next task
was to “craft” a set of observed excretions that would be due only to the
inhalation exposures. This was done as follows. First, rates of MnBP
excretion between urination events were ascertained for each individual
from the hood-on experiments. Then, these hood-on excretion rates were
used to amend the hood-off excretions for each participant, so that a new
set of “observed” excretions from the hood-off experiments can represent
inhalation-only excretions. These are not “observed” excretions in the true
sense of raw data from the experiment; they will be hereafter described as
“crafted” excretions for this reason. This subtraction was not straightfor-
ward, however, because the chamber concentration for the two scenarios
was somewhat different and urination times and volumes do not align for
the two experiments. Therefore, it was necessary to convert observations
from the hood-on experiments to time-varying excretion rates to use in the
hood-off experiments for each participant and account for the difference
in the times of urine events, and for the chamber concentrations. An
example of this procedure for participant P1 is shown in Table 1 for the
hood-on experiment. The normalized excretion rate, of MnBP only, for each
urination interval is determined by dividing the excreted metabolite mass
by the time interval since the last urination and then multiplying by the
ratio of the hood-off and hood-on chamber concentrations (140/123). As
shown in Table 2, these results are aligned with the excretion rates from
the hood-off experiments and subtracted. If that subtraction resulted in a
total of < 0, then the excreted amount was set to 0 (see several such events
in the last column of Table 2). As seen in Table 2, the total excretion from
Table 1. Calculation of the rate of excretion for Participant 1, P1,
resulting from transdermal uptake of DnBP when wearing a hood
(see text for more detail).
Interval in
hoursa
Mass MnBP
excreted, μg
Hourly rate of
excretion of
MnBP, μg/hb
Hourly rate of
MnBP excretion
normalized, μg/hc
0–3.50 12 3.4 3.9
3.50–7.17 44 12.0 13.7
7.17–10.25 49 15.7 17.9
10.25–11.25 7 6.8 7.7
11.25–12.25 5 5.6 6.4
12.25–17.50 39 7.4 8.4
17.50–24.83 64 8.7 9.9
24.83–29.50 6 1.1 1.3
29.50–33.67 10 2.6 3.0
33.67–37.50 9 2.4 2.7
37.50–46.67 19 2.0 2.3
46.67–50.83 8 1.9 2.2
50.83–52.42 1 0.5 0.6
52.42–55.50 2 0.9 1.0
aHour “0” is when the participant enters the chamber. bThe hourly rate of
excretion is calculated as M(t1)/(HR(t1)−HR(t0)), where M is the mass (μg) of
MnBP excreted, HR(t0) and HR(t1) are the times (h) for the previous
event and the current event, respectively. For example, the rate between
the ﬁrst and second excretion is (44)/(7.17− 3.5)= 12.0 cAs the hourly
rate of excretion, column 2, was based on “hood-on” experiments, this rate
was normalized considering the difference in air concentration in
the adjustment applied to the “hood-off” experiments. In this case,
the “hood-on” concentration was 123 μg/m3, whereas for “hood off” the
concentration was 140 μg/m3, necessitating an upward adjust of 140/123
or 1.14.
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that experiment over 54 h (starting from when P1 entered the chamber at
time 0) was 678 μg, and after subtraction for the dermal contribution, the
total excretion was reduced to 372 μg. Therefore, this total of 372 μg
represents that portion of the total excretion due only to inhalation. This
procedure was followed for all participants, P1 to P6.
Finally, it is noted that none of the simulations included background
intakes of DnBP that the participants experienced once leaving the
chamber and which undoubtedly inﬂuenced excretion of DnBP metabo-
lites in the 48 h after leaving the chamber. The implications of this decision
are discussed in the Results section below.
RESULTS
Figure 1 shows an example set of inputs, calculated from the
dynamic model,18 to one of the linked model simulations. These
modeled inputs include the rate of absorbed doses from
inhalation and dermal uptake for participant P1 in the “hood
off” experiments. The rate is expressed in units of μg/5 min (5 min
is the time step of the linked model). As seen, the modeled
inhalation dose is constant over 6 h of the experiment and then
stops upon leaving the chamber, while the modeled dermal dose
continues and even peaks once outside the chamber. In this
example, over 54 h modeled dermal uptake loads about twice as
much DnBP into the blood (1210 μg) as modeled inhalation intake
(588 μg).
Figures 2, 3, 4 show comparisons of predicted and observed
metabolite (MnBP and 3OH-MnBP) concentrations and cumulative
mass excreted in urine for participant P1 for the three simulations:
hood on, hood off, and inhalation only. The comparable ﬁgures for
the other participants, P2 to P6, are shown in the Supplementary
Materials. The general trends described here for P1 are the same
for both metabolites and for all volunteers in the three sets of
simulations. Five key trends are observed from the results shown
in Figures 2, 3, 4:
(1) The timing of the peak urine metabolite concentrations
and the rate of decline of concentrations to background
levels after about the ﬁrst 24–30 h (starting at time 0 when the
participants enter the chamber) is well captured by the
linked model.
(2) The relationship between MnBP and 3OH-MnBP urine
concentrations and mass excretions appear reasonably well
captured by the linked model. Speciﬁcally, MnBP concentra-
tions and cumulative excretions are more than an order of
magnitude higher than those for 3OH-MnBP, and this is seen
in both the data and the model predictions.
(3) Although the overall patterns of excretions of the two
metabolites seem well predicted for P1, there is nonetheless
an overprediction in concentrations and cumulative excretions
of both metabolites over time. This overprediction is an
anticipated contribution from the dermal uptake algorithm
(see discussion in the Inhalation Intake and Dermal Uptake
subsection in the Methods section above) and occurs from
∼ 10 h onwards (the participants leave the chamber at 6 h).
The same occurs with all participants in the simulations. As
seen in Figure 1, because of storage in the stratum corneum
the delivery of parent DnBP to blood continues throughout
the 54 h of simulation, and peaks at ∼ 10 h, and this is 4 h after
leaving the chamber.
(4) For the crafted “inhalation-only” simulations, only MnBP was
modeled, and the results are shown in Figure 4. The overall
patterns in both concentrations and cumulative excretions
appear well captured for participant P1. The predicted and
observed concentrations are in fairly good agreement as are
the cumulative excretions; the overprediction noted in
observation 3 above is not seen for the crafted inhalation
simulations.
(5) The participants in the hood-on and hood-off simulation sets,
each of which included the dermal exposure pathway, appear
to have been affected rather quickly by the elevated DnBP in
the air. Speciﬁcally, the observed concentrations in the ﬁrst
and also the second urine event for these scenarios was higher
than predicted by the model. This is seen in Figures 2 and 3.
However, the same is not true for the inhalation-only scenario
in Figure 4, where dermal impacts are removed from the input
stream and the excretions due to dermal uptake are also
removed from the crafted excretions. In that case, there is a
closer match between predicted and observed concentrations
in the ﬁrst two urine events. These trends are seen as well in
Table 2. Calculation of the removal of excretion mass of MnBP from
urine events of participant P1 that would be due to transdermal
uptake in the hood-off experiment (see text for more detail).
Houra Total mass
MnBP
excreted, μgb
Rate of
excretion
applied, μg/hc
Number of
hours since
last excretiond
Mass excreted
due to inhalation
only, μge
3.08 69 3.9 3.08 57.0
5.25 116 13.7 2.17 86.3
6.42 85 13.7 1.17 69.0
8.33 93 17.9 1.91 58.8
11.08 45 14.1 2.75 6.2
12.42 16 7.7 1.34 5.7
13.25 6 8.4 0.83 0.0
13.58 5 8.4 0.33 2.2
23.25 143 9.5 9.67 51.1
26.00 23 6.8 2.75 4.3
31.08 9 1.5 5.08 1.4
33.33 5 3 2.25 0.0
37.42 7 2.7 4.09 0.0
41.33 5 2.3 3.88 0.0
46.50 11 2.2 5.17 0.0
49.42 7 2.2 2.92 0.6
51.42 1 2.2 2.00 0.0
54.33 32 0.7 2.91 30.0
Total 678 372
aHour “0” is when the participant enters the chamber. bThe observed
unadjusted data from the hood-off experiment for P1. cApproximated
excretion rates from transdermal uptake determined from Table 1. dHour of
the excretion minus the hour of the preceding excretion. eOriginal mass
excretion minus (hours since last excretion ×hourly excretion rate); if the
“corrected mass” is calculated to be ˂0, it is set to zero. For example, for the
excretion at 5.25 h, the corrected mass is: 116–(2.17 × 13.7)= 86.3 μg.
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Figure 1. Model inputs of the rate of absorbed DnBP delivered to
the blood (in units of μg/5 min increment) from the 6 h chamber
exposure for P1, “Hood Off”, where the average air concentration
was 140 μg/m3.
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other participants, as shown in the ﬁgures of the
Supplementary Information. There appears an initial rush of
airborne DnBP into and through the skin to quickly get into
the body and be excreted; this is not captured by the dermal
penetration model. The more immediate impact appears to be
better captured for the inhalation pathway. Ultimately, fast
initial dermal uptake has little effect on longer-term excretions,
and real-world situations are likely to entail conditions more
closely aligned to equilibrium and steady state compared with
a sudden exposure to elevated airborne DnBP.
Table 3 shows the observed and predicted cumulative
excretions over 54 h for all participants and the three simulation
sets. The results of participant P1 in Table 3 are the ﬁnal points
in the cumulative graphs shown in Figures 2, 3, 4. Generally,
observed cumulative excretions of MnBP in the hood-on experi-
ments (set 1; avg 376 μg) are similar to the crafted excretions from
inhalation-only (set 3; avg 311 μg). The cumulative observed
excretion of MnBP with the hood-off experiments (set 2, both
pathways) averages 663 μg, just about equal to the sum of hood-
on and inhalation-only cumulative excretions. Even further, this
sum also works out for each individual (not just the group
average). For example, the hood-off cumulative excretion of P2
was 1020 μg, similar to the sum of the hood-on cumulative
excretion and the inhalation-only cumulative excretion for P2,
983 μg (590+393 μg). The individual with the lowest observed
excretion for the hood-off experiment, P5 at 254 μg, had an
observed sum of 295 μg. These equivalencies are not unexpected,
and indeed they provide a secondary conﬁrmation of the
approach used to craft an inhalation-only set of individual-
speciﬁc excretions; the sum of an inhalation-only excretion and a
dermal-only excretion should equal the observed “total” excretion
when both pathways are involved.
The anticipated overprediction because of the transdermal
uptake algorithm is reﬂected in the modeled excretions. For the
hood-on scenario, the model predicts an average cumulative
excretion of 676 μg that is nearly double the average of 376 μg
observed for that scenario. For the inhalation-only scenario, the
model predicts an average cumulative excretion of 340 μg that is
very near the average crafted cumulative excretion of 311 μg.
Indeed, the rank ordering of low to high excretions (from P5
lowest to P3 highest) is identical for both observed and predicted
in this inhalation-only scenario. Similar to the hood-on scenario,
the model overpredicts excretions for hood-off scenario, aver-
aging 1018 μg predicted compared with the average observed of
663 μg. Again, this difference is anticipated and due to the model
overpredicting excretion when the dermal pathway is involved, as
was discussed in the Methods section above.
This observation that the model appears to do well in
characterizing inhalation intake and excretion but not as well in
characterizing dermal uptake and excretion is consistent with the
overpredictions of transdermal uptake of DnBP described in
Morrison et al.18 They performed a sensitivity analysis on key
parameters and suggested mechanisms that may reduce DnBP
uptake; results are summarized in Figure 5 of Morrison et al.18
Transdermal uptake is especially sensitive to skin surface lipids
because of the relatively large DnBP partition coefﬁcient between
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Figure 2. Comparison of predicted (blue lines with dots for predictions) and observed (red lines with dots for measurements) DnBP metabolite
spot sample excretions for participant P1 in the “Hood-On” Simulation set. The four subgraphs are: (a) MnBP spot sample urine concentrations,
(b) cumulative MnBP excretions, (c) 3OH-MnBP spot sample urine concentrations, and (d) cumulative 3OH-MnBP excretions.
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lipids and air. Certain partition coefﬁcients used in the transdermal
model—those between skin surface lipids and air (Kssl_g) and
between the stratum corneum and air (Ksc_g)—are difﬁcult to
estimate for DnBP and may be off as much as an order of
magnitude (a table of physical and chemical properties of DnBP is
provided in Supplementary Materials). Removal of skin surface
lipids by transfer to clothing or washing was also predicted to
signiﬁcantly reduce dermal uptake of DnBP (but not DEP). A single
transfer of skin surface lipids to clothing after participants leave
the exposure chamber was predicted to reduce DnBP uptake by
30%.18 Further removal by washing or transfer to new clothing or
bedding would also reduce uptake. Subject-to-subject variability
may also be inﬂuential.
Weschler et al.10 observed that normalized dermal uptake of
both phthalates studied in these chamber experiments, DEP and
DnBP, increased with age, with the lowest amounts of excreted
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metabolites in the hood-on experiments seen in the youngest
participant. (The ages of the participants were 27 (P5), 33 (P1),
34 (P4), 37 (P6), 47 (P2), and 66 (P3) years.) The agreement
between modeled and measured results is best for the 66- and
47-year-old subjects and worst for the 27-year-old subject.
However, the only person-speciﬁc factor considered in the dermal
permeation modeling was exposed body surface area. Neither skin
thickness nor skin hydration (which both decrease with age) were
measured and could not be included in the dermal model. The
sensitivity analysis in Morrison et al.18 suggested that normal
variability in the thickness of the skin surface lipids and stratum
corneum could result in uptake that varies by a factor of two or
more. Diffusivity of DnBP in the stratum corneum is also uncertain
and given its high Kow and molecular weight, it is very difﬁcult to
measure for the isolated stratum corneum. Instead, it was
calculated using the methodology in Gong et al.17 for partially
hydrated stratum corneum but was not varied independently.
Instead, it was varied with the reciprocal of the partition
coefﬁcient (consistent with Gong et al.17); predicted uptake was
weakly sensitive to this parameter.
The metabolic conversion model for DnBP was based on an oral
dose of DnBP, and was calibrated based on the internal meta-
bolism from a single individual (see Lorber and Koch25) without
any changes made for the different individuals of the experiment.
This appeared to work well for inhalation. However, metabolism
may differ in some respects for dermal uptake, as in the latter case
DnBP bypasses enzymes in the stomach and intestines. Therefore,
there may be a need to modify metabolic parameters in the PK
model when applied to the dermal pathway. Finally, it was noted
in the Methods section that background exposures to DnBP once
leaving the chamber were not considered in the modeling
but undoubtedly inﬂuenced excretion of metabolites in the 48 h
after leaving the chamber. Had background exposures been
considered, there would have been higher predicted excretions of
MnBP and 3OH-MnBP, and a larger gap between predicted and
observed excretions of metabolites. However, we conclude that
the impact of not considering background exposures would be
small. Weschler et al.10 calculated the possible background-related
excretions of MnBP and 3OH-MnBP for each participant for the
time outside the chamber during 6–54 h based on observed MnBP
and 3OH-MnPB excretions in the prechamber urination events and
the last urination event near 54 h. Based on their calculations, the
average excretion of MnBP and 3OH-MnBP over all participants for
7–54 h due only to background sources would be 68 and 6.1 μg,
respectively. To put this in perspective, the total observed
excretion of the metabolites including one urination event within
the chamber and then all events outside the chamber averaged
377 μg MnBP and 31 μg 3OH-MnBP for hood-on experiments, and
658 μg MnBP and 63 μg 3OH-MnBP for hood-off experiments. On
average, only ∼ 18% of MnBP excretions for the hood-on and 10%
of excretions for the hood-off experiments may have been due to
background exposures once outside the chamber.
DISCUSSION
This study linked models of DnBP transdermal uptake and
inhalation intake to a simple PK model to predict excretions of
DnBP metabolites in urine over the 54 h period. The observed data
were from a chamber experiment described in Weschler et al.,10
where six mostly bare-skinned (shorts only) male adults were
exposed to elevated levels of DnBP in air over a 6 h period, and full
volumes of urine were obtained from the time the participants
entered the chamber until 54 h later.
A key assumption in the modeling was that the chamber air
concentrations were not limited in any way by inhalation and
dermal uptake of the three individuals within the chamber for 6 h.
A simple mass balance was conducted that showed that removal
by the individuals through modeled inhalation and dermal uptake
was not limiting (calculation not shown). Indeed, consecutive
hourly samples of air while the subjects were in the chamber
showed consistent air concentrations. Therefore, we concluded
that possible removal by exposure of the individuals in the
chamber would not limit the amount available for any of them
over time. The concentrations used in modeling were the average
of the multiple samples collected during the exposure period.
The linked model generally captured the patterns of exposure
and internal metabolism with regard to the timing of peak
concentration, rapid decline to background concentrations, and
the relationship between the two key metabolites of DnBP
that were modeled (MnBP and 3OH-MnBP). However, there is a
pattern of overprediction associated with dermal uptake that
was anticipated based on the results of Morrison et al.18 We have
compared observations and model predictions using results for a
single representative participant (Figures 1, 2, 3, 4), for all
participants (Table 3), and average results (text). The graphical
patterns shown in Figures 2, 3, 4 for participant P1 are shown for
all participants in the Supplementary Materials. However, we have
not applied any statistical goodness-of-ﬁt tests between model
predictions and observations. Such tests would be fated to show
poor results where dermal uptake was modeled because of this
pattern of overprediction.
Table 3. Observed and predicted total excretions over 54 h (6 h in the
chamber and then additional 48 h) for the six participants, P1 to P6, for
hood on, hood off, and inhalation exposure only.
Participant Cumulative excretions, μg
MnBP 3OH-MnBP
Observed Predicted Observed Predicted
(1) Hood-on experiments
P1 274 697 38 61
P2 590 682 57 60
P3 442 548 24 48
P4 307 696 22 61
P5 162 727 14 64
P6 484 705 31 62
(2) Hood-off experiments
P1 649 1189 81 104
P2 1020 1216 122 106
P3 906 1122 51 98
P4 529 881 32 77
P5 254 824 32 72
P6 589 874 62 77
(3) Inhalation-only simulationsa
P1 342 366 Not applicable;
inhalation simulations
focused only on MnBP
P2 393 411
P3 471 480
P4 306 293
P5 133 209
P6 220 279
(1) Hood on, where the exposure is dermal absorption only; (2) hood off,
where the exposure is both inhalation and dermal absorption; and (3)
inhalation exposure only. aThese simulations were tailored to simulate
inhalation only starting from the Hood-Off data set. The input stream was
altered to only include inhalation inputs and the “observed” excretions
were renamed “crafted” to indicate that they were developed starting from
the hood-off experiments and amended to remove that portion of the
total excretion that was surmised to be due to dermal uptake. See text for
more detail.
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There are two consistent patterns of differences between
observations and modeled results associated with the dermal
uptake pathway. In the ﬁrst pattern, metabolites associated with
transdermal uptake appear in urine much quicker than is modeled
by the transdermal/toxicokinetic model. This was seen in higher
observed concentrations in the ﬁrst urine event while the
participants were in the chamber, and to a lesser extent in the
second urine event shortly after participants left the chamber. This
pattern was not seen in the crafted inhalation-only scenarios. We
are unclear as to the cause of this observation and did not pursue
understanding or modeling it further. A second pattern that was
observed was that the model then continues to overpredict
excretions starting at approximately the 10 h mark, 4 h after
participants leave the chamber. Ultimately, after 54 h, the model
has predicted between 1.1 and 4.5 times the observed cumulative
excretion of MnBP and 3OH-MnBP when transdermal uptake is
involved, the hood-on and hood-off scenarios (see Table 3).
Despite a tendency for the present linked model to overpredict
DnBP metabolite excretions, we are not disappointed with the
results. Certainly, better ﬁts could be obtained with different
plausible model parameters. As discussed, model sensitivity
exercises in Morrison et al.18 showed that a one-time removal of
skin surface lipids, as might occur with donning of clothing for
example, resulted in reduced dermal penetration of DnBP. We did
not include any removal events that might include bathing in
addition to donning and removing clothing. However, our intent
was to assign model parameters using the best available
information, which may have been previous calibrations (as in
the toxicokinetic model), or using best literature values. Generally,
we conclude that this exercise has provided a positive proof of
concept of linking two dose models (transdermal and inhalation)
to an internal kinetic model to characterize exposure to
airborne DnBP.
This linked model gives us a tool to estimate the contribution
that airborne DnBP can make to overall DnBP exposure in different
settings. We demonstrate the linked model’s capabilities with a
simple characterization of general population exposure to air-
borne DnBP within the United States using the following
approach. First, a typical background air concentration of DnBP
was estimated based on measured levels reported in the
literature. Then, the intake models were run to steady state to
determine daily dermal and inhalation intakes. Intakes were run
through the toxicokinetic model as was done for the chamber
experiments, and daily steady-state mass of MnBP that gets
delivered to the model’s “bladder” (awaiting excretion) were
determined. An amount of MnBP delivered over 24 h was divided
by an average daily urine volume to get a representative concen-
tration of MnBP. Finally, this was compared with representative
urine concentrations of MnBP for US adults as measured in
recent cycles of NHANES (National Health and Nutritional
Evaluation Survey from CDC4). We emphasize that this is a simple
demonstration of what can be accomplished with the linked
model. There are a wide range of possible input variables and
parameters, as will be described, and this should not be construed
as a deﬁnitive attempt to characterize inhalation and dermal
exposures to DnBP in the general US population.
The median airborne DnBP concentration reported by Rudel
et al.3 for 120 Cape Cod homes was 0.22 μg/m3. The US EPA CTEPP
(Children’s Total Exposure to Persistent Pesticides and Other
Persistent Organic Pollutants) study reported median airborne
concentrations of 0.23 μg/m3 in 129 North Carolina homes,
0.25 μg/m3 in 127 Ohio homes, 0.38 μg/m3 in 13 North Carolina
daycare facilities, and 0.32 μg/m3 in 16 Ohio day-care facilities.28
Gaspar et al.2 report a median air concentration of 0.52 μg/m3 for
40 California day-care facilities. Tran and Kannan29 collected 60
indoor air samples from homes (n= 20), ofﬁces (n= 7), laboratories
(n= 13), schools (n= 6), salons (n= 6), and public places (n= 8) in
Albany, NY, and found a median of 0.06 μg/m3 over all settings;
the highest concentrations were in salons with a median of
0.31 μg/m3. Based on these studies, we selected a representative
air concentration of 0.2 μg/m3. Furthermore, we assume that this
total concentration is all in the gas phase (at typical concentra-
tions of indoor airborne particles, ∼ 95% of DnBP is in the gas
phase).30 Daily inhalation exposures were calculated assuming an
hourly inhalation rate of 0.7 m3/h, similar to the “light intensity”
rate of inhalation of 0.72 m3/h recommended in the EPA EFH.26
Under these conditions, the total daily intake by inhalation is
calculated as 0.042 μg/kg per day ([0.7 m3/h × 24 h/day × 0.2 μg/
m3)/80 kg, where 80 kg is the recommended adult body weight in
EPA26). We ran the transdermal model to steady state with all key
parameters unchanged from the chamber experiments, with the
exception of the exposed body surface area that we assumed was
1.0 m2. The total body surface area for adults is ∼ 2 m2, with the
head, arms, and hands (typical body parts assumed to be
uncovered in dermal exposure scenarios) about one-quarter of
that. The exposed area of 1.0 m2 assumes slight attenuation by
clothing. Clothing can either decrease or amplify dermal uptake,
depending on its history before it is worn.31 With these
assumptions, the transdermal model was run to steady state,
resulting in an estimated daily transdermal uptake of DnBP of
0.14 μg/kg per day. Note that for this simple example, transdermal
uptake is ∼ 3 times higher than inhalation intake. This is not the
same as the result for the 6 h chamber experiments that showed
comparable intakes for the two pathways. However, 6 h is too
short a time for dermal uptake to approach steady state. At steady
state (and with all model parameters as assigned), the model
indicates that transdermal uptake exceeds inhalation by about a
factor of three.
The linked models were run with these steady inputs from
inhalation intake and dermal uptake for 4 days; the mass of MnBP
excreted on the fourth day (steady state attained) was 9.9 μg, or
on a body weight basis, 0.124 μg/kg per day. If we divide this
excretion of 9.9 μg by an average adult urine volume of 1.5 l32
(comparable to “reference values” of 1.6 l for males and 1.2 l for
females in ICRP33), we calculate an MnBP urine concentration of
6.6 μg/l. The geometric mean concentrations of MnBP found in
NHANES surveys 2005/6, 2007/8, and 2009/10 were 19.6, 18.9 and
14.6 μg/l, respectively.4 It is noted that the dermal uptake model
was found to overpredict penetration of DnBP. Uptake is sensitive
to the removal of DnBP by mechanisms not included in this
modeling exercise such as skin surface lipid transfer to clothing
and removal by bathing.18 Hence, the prediction in this simple
demonstration was more likely higher than would be predicted if
such processes had been included. In addition, key inputs such as
the typical background air concentration and the exposed body
surface area were assigned values that may not accurately
characterize the general US population. Finally, type of clothing
worn and laundering practices can inﬂuence uptake of DnBP via
the dermal pathway. Still, assuming our assignments are reason-
able for purposes of demonstration, a prediction suggesting that
airborne concentrations of DnBP could explain upwards of 25% of
total exposures is fairly remarkable. Without being too precise,
given all the assumptions and uncertainties of this simple exercise,
we conclude that the combined pathways of inhalation and
dermal uptake of airborne DnBP contribute a substantial fraction
of exposure to DnBP in the general US population.
The chamber experiments described in Weschler et al.10
demonstrated the importance of the dermal pathway for exposure
to DnBP and DEP. The linked models of this paper show the
feasibility of additionally studying this pathway through the use of
such models, and the application of the linked models in this
example of general population exposure demonstrates their
utility. Further exercises could be undertaken for DnBP exposures
in different settings, and similar linked modeling could be done in
the case of DEP, the other phthalate studied in the chamber
experiments.
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